Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
This is a single-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy
Advanced NSCLC
DRUG: JS207 injection
Objective response rate (ORR), According to the efficacy evaluation criteria for solid tumors version 1.1 (RECIST V1.1): to evaluate objective response rate (ORR), 1.5years
Disease control rate (DCR), According to the efficacy evaluation criteria for solid tumors version 1.1 (RECIST V1.1): to evaluate disease control rate (DCR), 2years|Duration of response (DOR), According to the efficacy evaluation criteria for solid tumors version 1.1 (RECIST V1.1): to evaluate duration of response (DOR), 2years|Progression-free survival (PFS), According to the efficacy evaluation criteria for solid tumors version 1.1 (RECIST V1.1): to evaluate progression-free survival (PFS), 1.5years|Overall survival (OS), According to the efficacy evaluation criteria for solid tumors version 1.1 (RECIST V1.1): to evaluate overall survival (OS), 2years|AE, Incidence and serverity of adverse events(AE),abnormal changes in laboratory and other tests with clinical significance, 2years|Abnormal changes in laboratory, Incidence and serverity of abnormal changes in laboratory and other tests with clinical significance, 2years
the trough concentrations (PK), to characterize the tough concentration of JS207, 1.5years|Neutralizing antibody(Nab), to characterize the neutralizing antibody of JS207, 1.5years|Antidrug antibodies (ADA), to characterize antidrug antibodies of JS207, 1.5years
This is a single-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy